The genetic cardiomyopathies market size was valued at USD 1.7 billion in 2023, driven by the rising emphasis on preventing cardiac failures. The market is expected to grow at a CAGR of 13.3% during the forecast period of 2024-2032, with the values likely to rise from USD 2 billion in 2024 to USD 5.4 billion by 2032.
Genetic cardiomyopathy or familial hypertrophic cardiomyopathy is a heart condition that thickening of the cardiac muscle. In this case, the cardiac thickening usually occurs in the muscular wall (interventricular septum) that separates the left ventricle (lower chamber of heart) from right ventricle. Genetic cardiomyopathy may impede the flow of oxygen rich blood from the heart. This in turn, may lead to an abnormal heartbeat (arrhythmias) in the patients.
Common symptoms include chest pain, shortness of bread, palpitations, dizziness, or fainting. However, the symptoms differ from person to person, even within the same family. People suffering from genetic cardiomyopathy are at a sudden risk of death, despite having no symptoms.
Genetic cardiomyopathy is a commonly inherited cardiac illness, affecting approximately 2-5 in a 1000 people. Non-pharmacological treatments like septal myectomy and alcohol septal ablation are frequently used to improve long-term quality of life in patients suffering from genetic cardiomyopathy. Over the years, significant advancements in the non-invasive and pharmacological treatment have been observed.
In 2023, the FDA approved a drug called Mavacamtem, popularly known as Camzyos, as a novel alternative for treating genetic cardiomyopathy. This new class drug, a myosin inhibitor, works by cutting down myosin levels which are present in abundance in the patients.
The genetic cardiomyopathies market value is expected to see a significant hike in the forecast period, with the rising emphasis on using novel techniques to fight the ailment. New study set-ups like induced pluripotent stem cells, three dimensional printing of cells, use of scaffolds and engineered heart tissue, are now being looked upon as a treatment alternative. Moreover, extensive knowledge on mutated proteins, protein quality control, and toxicity has opened new avenue of contemporary techniques like gene editing and repair using CRISPR Cas9, customised drugs and antisense therapies to develop an efficient and accurate treatment for the disease.
With a rising preference for precision medicine, researchers are now combining machine learning guided ECG and imaging analyses to facilitate new targeted drugs. Hence, we can a anticipate a substantial genetic cardiomyopathies market growth in the forecast period.
Market Breakup by Disease Type
Market Breakup by Drug Type
Market Breakup by Route of Administration
Market Breakup by End User
Market Breakup by Region-7MM
Genetic cardiomyopathy is a major cause of heart failure. With the rise in population, obesity, geriatric population, the North American region has been susceptible to number of heart failures, as a result, it has dominated the genetic cardiomyopathies market share in the historic period. Effective measures have been taken the government to mitigate the number of morbidities, which have been successful to an extent. Moreover, the presence of prominent healthcare market players has made a huge impact with regular research and conducting clinical trials to bring the best possible treatment for the patients.
In some cases, genetic cardiomyopathy may also lead to heart transplantation. Therefore, the Asian-pacific region can expect a hike in the forecast period, owing to its increasing popularity as medical tourism space. In addition, presence of an aging population is also fuelling investments and government initiatives to develop a quality infrastructure that can drive a prominent research and development in the contemporary treatment alternatives.
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
|Scope of the Report||
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|Breakup by Disease Type||
|Breakup by Drug Type||
|Breakup by Route of Administration||
|Breakup by End User||
|Breakup by Region-7MM||
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Genetic Cardiomyopathies Overview
3.1 Guidelines and Stages
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Genetic Cardiomyopathies Epidemiology Analysis-7MM
5.1 Epidemiology Overview (2016-2031)
5.2 United States Genetic Cardiomyopathies Epidemiology (2016-2031)
5.3 EU-4 and United Kingdom Genetic Cardiomyopathies Epidemiology (2016-2031)
5.4 Japan Genetic Cardiomyopathies Epidemiology (2016-2031
6 Genetic Cardiomyopathies Market Overview
6.1 Genetic Cardiomyopathies Market Historical Value (2017-2023)
6.2 Genetic Cardiomyopathies Market Forecast Value (2024-2032)
7 Genetic Cardiomyopathies Market Landscape
7.1 Genetic Cardiomyopathies Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Genetic Cardiomyopathies Product Landscape
7.2.1 Analysis by Indication
7.2.2 Analysis by Treatments
7.2.3 Analysis by Route of Administration
8 Genetic Cardiomyopathies Treatment Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Genetic Cardiomyopathies Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Genetic Cardiomyopathies Market Segmentation
11.1 Genetic Cardiomyopathies Market by Disease Type
11.1.1 Market Overview
11.1.2 Dilated Cardiomyopathy
11.1.3 Hypertonic Cardiomyopathy
11.1.4 Restrictive Cardiomyopathy
11.2 Genetic Cardiomyopathies Market by Drug Type
11.2.1 Market Overview
11.2.5 Cardiac Glycosides
11.3 Genetic Cardiomyopathies Market by Route of Administration
11.3.1 Market Overview
11.4 Genetic Cardiomyopathies Market by End User
11.4.1 Market Overview
11.4.4 Ambulatory Services Centres
11.5 Genetic Cardiomyopathies Market by Region-7MM
11.5.1 Market Overview
11.5.2 United States
11.5.3 EU-4 and the United Kingdom
12 United States Genetic Cardiomyopathies Market
12.1 U.S. Genetic Cardiomyopathies Market Historical Size (2017-2023)
12.2 U.S. Genetic Cardiomyopathies Market Forecast Size (2024-2032)
12.3 Market Size by Drug Type
13 EU-5 and the United Kingdom Genetic Cardiomyopathies Market
13.1 EU-5 and the United Kingdom Genetic Cardiomyopathies Market Historical Size (2017-2023)
13.2 EU-5 and the United Kingdom Genetic Cardiomyopathies Market Forecast Size (2024-2032)
13.3 Market Size by Drug Type
14 Japan Genetic Cardiomyopathies Market
14.1 Japan Genetic Cardiomyopathies Market Historical Size (2017-2023)
14.2 Japan Genetic Cardiomyopathies Market Forecast Size (2024-2032)
14.3 Market Size by Type
15 Regulatory Framework
15.1 US FDA
15.2 EU EMA
15.3 JAPAN PMDA
16 Patent Analysis
16.1 Analysis by Type of Patent
16.2 Analysis by Publication year
16.3 Analysis by Issuing Authority
16.4 Analysis by Patent Age
16.5 Analysis by CPC Analysis
16.6 Analysis by Patent Valuation
16.7 Analysis by Key Players
17 Grants Analysis
17.1 Analysis by year
17.2 Analysis by Amount Awarded
17.3 Analysis by Issuing Authority
17.4 Analysis by Grant Application
17.5 Analysis by Funding Institute
17.6 Analysis by NIH Departments
17.7 Analysis by Recipient Organization
18 Clinical Trials Analysis
18.1 Analysis by Trial Registration Year
18.2 Analysis by Trial Status
18.3 Analysis by Trial Phase
18.4 Analysis by Therapeutic Area
18.5 Analysis by Geography
19 Funding Analysis
19.1 Analysis by Funding Instances
19.2 Analysis by Type of Funding
19.3 Analysis by Funding Amount
19.4 Analysis by Leading Players
19.5 Analysis by Leading Investors
19.6 Analysis by Geography
20 Partnership and Collaborations Analysis
20.1 Analysis by Partnership Instances
20.2 Analysis by Type of Partnership
20.3 Analysis by Leading Players
20.4 Analysis by Geography
21 Supplier Landscape
21.1 Novartis International AG
21.1.1 Financial Analysis
21.1.2 Product Portfolio
21.1.3 Demographic Reach and Achievements
21.1.4 Mergers and Acquisition
21.2 Merck & Co.
21.2.1 Financial Analysis
21.2.2 Product Portfolio
21.2.3 Demographic Reach and Achievements
21.2.4 Mergers and Acquisition
21.3 Teva Pharmaceuticals
21.3.1 Financial Analysis
21.3.2 Product Portfolio
21.3.3 Demographic Reach and Achievements
21.3.4 Mergers and Acquisition
21.4 Mylan N.V
21.4.1 Financial Analysis
21.4.2 Product Portfolio
21.4.3 Demographic Reach and Achievements
21.4.4 Mergers and Acquisition
21.5 Bristo Myers Squibb Company
21.5.1 Financial Analysis
21.5.2 Product Portfolio
21.5.3 Demographic Reach and Achievements
21.5.4 Mergers and Acquisition
21.6 Boston Scientific Corporation
21.6.1 Financial Analysis
21.6.2 Product Portfolio
21.6.3 Demographic Reach and Achievements
21.6.4 Mergers and Acquisition
21.7.1 Financial Analysis
21.7.2 Product Portfolio
21.7.3 Demographic Reach and Achievements
21.7.4 Mergers and Acquisition
21.8 Dickinson and Company
21.8.1 Financial Analysis
21.8.2 Product Portfolio
21.8.3 Demographic Reach and Achievements
21.8.4 Mergers and Acquisition
21.9 Critical Care Diagnostics Inc.
21.9.1 Financial Analysis
21.9.2 Product Portfolio
21.9.3 Demographic Reach and Achievements
21.9.4 Mergers and Acquisition
21.10.1 Financial Analysis
21.10.2 Product Portfolio
21.10.3 Demographic Reach and Achievements
21.10.4 Mergers and Acquisition
22 Genetic Cardiomyopathies Market - Distribution Model (Additional Insight)
22.2 Potential Distributors
22.3 Key Parameters for Distribution Partner Assessment
23 Key Opinion Leaders (KOL) Insights (Additional Insight)
24 Company Competitiveness Analysis (Additional Insight)
24.1 Very Small Companies
24.2 Small Companies
24.3 Mid-Sized Companies
24.4 Large Companies
24.5 Very Large Companies
25 Payment Methods (Additional Insight)
25.1 Government Funded
25.2 Private Insurance
*Additional insights provided are customisable as per client requirements.
The market attained a value of about USD 1.7 billion in 2023 driven by the rising focus on reducing the number of heart failures associated with genetic cardiomyopathies.
The market is anticipated to grow at a CAGR of 13.3% during the forecast period of 2024-2032, likely to reach a market value of USD 5.4 billion by 2032.
With the arrival of new medicines and techniques to treat genetic cardiomyopathies, the market has seen a substantial growth.
Recently, the FDA approved Mavacamtem, a new drug to treat genetic cardiomyopathy. Moreover, the integration of machine learning in diagnostics to develop precision medicine in the patients are the current market trends.
The major regions of the market include Japan, United States, EU-4 and the United Kingdom.
Major drug types used include anticoagulants, anti-hypertensives, antiarrhytensives, cardiac glycosides and others.
Dilated cardiomyopathy, hypertonic cardiomyopathy, restrictive cardiomyopathy, and others may affect patients.
Different routes of administration for the treatment market include oral and tropical.
The end users in the market include hospitals, clinics, and ambulatory services centres.
Key players involved in the market are Novartis International AG, Merck & Co., Teva Pharmaceuticals, Mylan N.V, Bristo Myers Squibb Company, Boston Scientific Corporation, Sanofi S.A., Becton, Dickinson and Company, Critical Care Diagnostics Inc., and Labcorp.
Single User License
Five User License
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.